Optimization of magnetic nanoparticle-assisted lentiviral gene transfer

Pharmaceutical Research

Volumn 29, Issue 5, 2012, Pages 1255-1269

  Trueck, Christina ^a,b   Zimmermann, Katrin ^a,b   Mykhaylyk, Olga ^c   Anton, Martina ^c   Vosen, Sarah ^a   Wenzel, Daniela ^a   Fleischmann, Bernd K ^a,b   Pfeifer, Alexander ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b NRW International Graduate Research School BIOTECH PHARMA   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Gene targeting; Lentiviral vectors; Local cell positioning; Magnetic nanoparticles; Transduction

Indexed keywords

LENTIVIRUS VECTOR; MAGNETIC NANOPARTICLE;

ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; EMBRYO; ENGRAFTMENT; EX VIVO STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE TARGETING; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VITRO STUDY; INTRACELLULAR SIGNALING; LENTIVIRINAE; MAGNETIC FIELD; MATERIAL COATING; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SURFACE CHARGE; VIRAL GENE DELIVERY SYSTEM; VIRUS ATTACHMENT; VIRUS PARTICLE;

ANIMALS; CATTLE; CELL LINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; MAGNETICS; MICE; NANOPARTICLES; TRANSGENES;

EID: 84862653211     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0660-x     Document Type: Article

References (44)

1. Pfeifer A, Verma IM. Virus vectors and their application. In: Howley PM, Knipe DM, Griffin D, Lamb RA, Martin A, Roizman B, Straus SE, editors. Fields Virology. Philadelphia: Lippincott-Raven Publishers; 2001. p. 469-91.
2. Naldini L. Lentiviruses as gene transfer agents for delivery to non-dividing cells. Curr Opin Biotechnol. 1998;9(5):457-63.
3. Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther. 2000;7(1):20-3.
4. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem. 2005;74:711-38.
5. Goff SP. Retroviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, editors. Fields virology, vol 2. 4th ed. Philadelphia: Lippincott-Raven Publishers; 2001. p. 1871-939.
6. Desrosiers RC. Nonhuman lentiviruses. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, Straus SE, editors. Fields Virology, vol 2. 4th ed. Philadelphia: Lippincott-Raven Publishers; 2001. p. 2095-121.
7. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature. 2010;467 (7313):318-22.
8. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326(5954):818-23.
9. Pariente N, Morizono K, Virk MS, Petrigliano FA, Reiter RE, Lieberman JR, et al. A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol Ther. 2007;15(11):1973-81.
10. Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Kruger A, et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther. 2002;9(2):102-9.
11. Hofmann A, Wenzel D, Becher UM, Freitag DF, Klein AM, Eberbeck D, et al. Combined targeting of lentiviral vectors and positioning of transduced cells by magnetic nanoparticles. Proc Natl Acad Sci U S A. 2009;106(1):44-9.
12. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, et al. Locoregional cancer treatment withmagnetic drug targeting. Cancer Res. 2000;60(23):6641-8.
13. Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473-80.
14. Chorny M, Fishbein I, Yellen BB, Alferiev IS, Bakay M, Ganta S, et al. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci U S A. 2010;107(18):8346-51.
15. Polyak B, Fishbein I, Chorny M, Alferiev I, Williams D, Yellen B, et al. High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci U S A. 2008;105(2):698-703.
16. Hatzopoulos AK, Folkman J, Vasile E, Eiselen GK, Rosenberg RD. Isolation and characterization of endothelial progenitor cells from mouse embryos. Development. 1998;125(8):1457-68.
17. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet. 2000;25(2):217-22.
18. Pfeifer A, Hofmann A. Lentiviral transgenesis. Methods Mol Biol. 2009;530:391-405.
19. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463-71.
20. Mykhaylyk O, Antequera YS, Vlaskou D, Plank C. Generation of magnetic nonviral gene transfer agents and magnetofection in vitro. Nat Protoc. 2007;2(10):2391-411.
21. Mykhaylyk O, Sanchez-Antequera Y, Vlaskou D, Hammerschmid E, Anton M, Zelphati O, et al. Liposomal magnetofection. Methods Mol Biol. 2010;605:487-525.
22. Mykhaylyk O, Vlaskou D, Tresilwised N, Pithayanukul P, Möller W, Plank C. Magnetic nanoparticle formulations for DNA and siRNA delivery. J Magn Magn Mat. 2007;311(1):275-81.
23. Sanchez-Antequera Y, Mykhaylyk O, Thalhammer S, Plank C. Gene delivery to Jurkat T cells using non-viral vectors associated with magnetic nanoparticles. Int J Biomedical Nanoscience and Nanotechnology. 2010;1(2/3/4):202-29.
24. Mykhaylyk O, Zelphati O, Hammerschmid E, Anton M, Rosenecker J, Plank C. Recent advances in magnetofection and its potential to deliver siRNAs in vitro. Methods Mol Biol. 2009;487:111-46.
25. Kowalski JB, Tallentire A. Substantiation of 25 kGy as a sterilization dose: a rational approach to establishing verification dose. Radiat Phys Chem. 1999;54(1):55-64.
26. Krill CE, Birringer R. Estimating grain-size distributions in nano-crystalline materials from X-ray diffraction profile analysis. Philos Mag A. 1998;77(3):621-40.
27. Mykhaylyk O, Zelphati O, Rosenecker J, Plank C. siRNA delivery by magnetofection. Curr Opin Mol Ther. 2008;10(5):493-505.
28. Mykhaylyk O, Steingotter A, Perea H, Aigner J, Botnar R, Plank C. Nucleic acid delivery to magnetically-labeled cells in a 2D array and at the luminal surface of cell culture tube and their detection by MRI. J Biomed Nanotechnol. 2009;5(6):692-706.
29. Haim H, Steiner I, Panet A. Synchronized infection of cell cultures by magnetically controlled virus. J Virol. 2005;79(1):622-5.
30. Benninghoff A, Drenckhahn D. Anatomie, Makroskopische Anatomie, Embryologie und Histologie des Menschen. 16 ed. Drenckhahn D, editor. München: Elsevier; 2004.
31. Dimitrov DS. Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol. 2004;2(2):109-22.
32. Tempaku A. Random Brownian motion regulates the quantity of human immunodeficiency virus type-1 (HIV-1) attachment and infection to target cell. Journal of Health Science. 2005;51(2):237-41.
33. Chomoucka J, Drbohlavova J, Huska D, Adam V, Kizek R, Hubalek J. Magnetic nanoparticles and targeted drug delivering. Pharmacological Research. 2010;62(2):144-9.
34. Shubayev VI, Pisanic Ii TR, Jin S. Magnetic nanoparticles for theragnostics. Adv Drug Deliver Rev. 2009;61(6):467-77.
35. Al-Deen FN, Ho J, Selomulya C, Ma C, Coppel R. Superparamagnetic nanoparticles for effective delivery of malaria DNA vaccine. Langmuir. 2011;27(7):3703-12.
36. Chorny M, Fishbein I, Alferiev I, Levy RJ. Magnetically responsive biodegradable nanoparticles enhance adenoviral gene transfer in cultured smooth muscle and endothelial cells. Mol Pharm. 2009;6 (5):1380-7.
37. Mykhaylyk O, Sanchez-Antequera Y, Tresilwised N, Doblinger M, Thalhammer S, Holm PS, et al. Engineering magnetic nano-particles and formulations for gene delivery. J Control Release. 2011;148(1):e63-4.
38. Plank C, Scherer F, Schillinger U, Bergemann C, Anton M. Magnetofection: enhancing and targeting gene delivery with superparamagnetic nanoparticles and magnetic fields. J Liposome Res. 2003;13(1):29-32.
39. Anton M, Wolf A, Mykhaylyk O, Koch C, Gansbacher B, Plank C. Optimizing Adenoviral transduction of endothelial cells under flow conditions. Pharm Res. 2011. doi:10.1007/ s11095-011-0631-2.
40. Sanchez-Antequera Y, Mykhaylyk O, van Til NP, Cengizeroglu A, de Jong JH, Huston MW, et al. Magselectofection: an integrated method of nanomagnetic separation and genetic modification of target cells. Blood. 2011;117(16):e171- 81.
41. Tresilwised N, Pithayanukul P, Holm PS, Schillinger U, Plank C, Mykhaylyk O. Effects of nanoparticle coatings on the activity of oncolytic adenovirus-magnetic nanoparticle complexes. Biomaterials. 2011;33:256-69.
42. Agopian K, Wei BL, Garcia JV, Gabuzda D. A hydrophobic binding surface on the human immunodeficiency virus type 1 Nef core is critical for association with p21-activated kinase 2. J Virol. 2006;80(6):3050-61.
43. Shin S, Shea LD. Lentivirus immobilization to nanoparticles for enhanced and localized delivery from hydrogels. Mol Ther. Apr;18 (4):700-6.
44. Rathel T, Mannell H, Pircher J, Gleich B, Pohl U, Krötz F. Magnetic stents retain nanoparticle-bound antirestenotic drugs transported by lipid microbubbles. Pharm Res. 2011. doi:10.1007/s11095-011-0643-y.